Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Clarify the effect of the treatment with 177-Lu-DOTA-octreotate, regarding a) tumour size b) biochemical response, c) prognostic factors such as proliferation markers and LD/ALP and type of tumour, d) quality of life, e) survival and f) progression free survival.
Inclusion criteria
- Patients with malignant neuroendocrine tumours, not amenable to surgical treatment or radiofrequency ablation. Renal, bone marrow and liver function must be sufficient